Claims
- 1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a tetra-substituted benzimidazole carbamate having the formula:
- 2. A method according to claim 1 wherein said cancer is selected from the group consisting of prostate cancer, melanoma, leukemia, pancreatic cancer, neuroblastoma, cervical cancer, ovarian cancer, stomach cancer, a sarcoma, a lymphoma, breast cancer, lung cancer and colon cancer.
- 3. A method according to claim 1 wherein said tetra-substituted benzimidazole carbamate has the formula:
- 4. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising a tetra-substituted benzimidazole carbamate having the formula:
- 5. A pharmaceutical composition of claim 4 further comprising a pharmaceutical carrier.
- 6. A pharmaceutical composition according to claim 4 comprising a pharmaceutical carrier and a safe and effective amount of a potentiator.
- 7. A pharmaceutical composition according to claim 6, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2′-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.
- 8. A pharmaceutical composition according to claim 4 further comprising a safe and effective amount of a chemotherapeutic agent.
- 9. A pharmaceutical composition according to claim 8 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, hormonal agent, Asparaginase and hydroxyurea.
- 10. A pharmaceutical composition according to claim 8 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, Paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole carbamate and Plicamycin.
- 11. A pharmaceutical composition according to claim 8 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Floxuridine, Mercaptopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine.
- 12. A pharmaceutical composition according to claim 8 further comprising a safe and effective amount of a potentiator.
- 13. A pharmaceutical composition according to claim 12, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2′-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.
- 14. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a combination therapy comprising (1) a tetra-substituted benzimidazole carbamate having the formula:
- 15. A liposome composition comprising a tetra-substituted benzimidazole carbamate selected from the group consisting of:
- 16. A liposome composition according to claim 15 selected from the group of consisting of unilamellar vesicle and multilamellar vesicles.
- 17. A liposome composition according to claim 16 formed from phospholipids cholesterol, stearylamine or phosphatidyl choline.
- 18. A tetra-substituted benzimidazole carbamate having the formula:
- 19. A tetra-substituted benzimidazole carbamate according to claim 18 wherein X, Y, Z and A are independently selected from the group consisting of bromo, fluoro, chloro, iodo and alkyl of less than 4 carbon atoms or alkoxy of less than 4 carbon atoms; R is (butylamino)carbonyl, and R1 is an alkyl group of less than 4 carbon atoms.
- 20. A tetra-substituted benzimidazole carbamate according to claim 18 wherein X and Y are identical and Z and A are identical and wherein X, Y and Z , A are independently selected from the group consisting of fluoro, chloro, bromo, iodo or methyl and R is (butylamino)carbonyl and R1 is methyl or ethyl.
- 21. A tetra-substituted benzimidazole carbamate according to claim 18 wherein X, Y and A are identical and wherein X, Y, A and Z are independently selected from the group consisting of fluoro, chloro, bromo, iodo or methyl and R is (butylamino)carbonyl and R1 is methyl or ethyl.
- 22. A tetra-substituted benzimidazole carbamate according to claim 18 wherein A, Y and Z are identical and wherein X, Y, Z and A are independently selected from the group consisting of fluoro, chloro, bromo, iodo or methyl and R is methyl, (butylamino)carbonyl or hydrogen and R1 is methyl or ethyl.
- 23. A tetra-substituted benzimidazole carbamate according to claim 18 having the formula:
- 24. A salt of a tetra-substituted benzirnidazole carbamate salt having the formula:
- 25. A prodrug of a tetra-substituted benzimidazole carbamate according to claim 18 wherein X, Y, Z and A are independently selected from the group consisting of bromo, fluoro, chioro, iodo and alkyl of less than 4 carbon atoms or alkoxy of less than 4 carbon atoms; R is (butylamino)carbonyl, and R1 is an alkyl group of less than 4 carbon atoms.
Parent Case Info
[0001] The present application is a continuation-in-part of U.S. Ser. No. 09/791,986, filed Apr. 28, 2000 and U.S. Ser. No. 09/562,709, filed Apr. 28, 2000. The patent applications are incorporated by reference herein.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09791986 |
Apr 2000 |
US |
Child |
09843562 |
Apr 2001 |
US |
Parent |
09562709 |
Apr 2000 |
US |
Child |
09843562 |
Apr 2001 |
US |